Skip to main
  1. Stocks
  2. Sophia Genetics SA
  3. Forecast
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is well positioned because its cloud-based, sequencer-agnostic SaaS platform monetizes the analysis layer, not the test, generating recurring usage fees while hospitals retain reimbursement risk and deepen adoption through in-house testing. Its moat compounds through a globally diverse network of roughly 1,000 institutions across 75 countries and more than 2.5 million genomic profiles, which improves algorithm performance, supports high retention, and expands use cases in clinical care and biopharma. Financially, 2025 revenue reached $77.3M, 2026 guidance is $92M–$94M, adjusted gross margin was 74.2% in 2025 and 75.4% in 1Q26, and the company targets adjusted EBITDA profitability in 2H27.

Bears say

Sophia Genetics is challenged by weak commercial execution, as 2024 revenue rose only 4% even while volumes increased 11%, implying a 6% to 7% decline in revenue per analysis and signaling softer monetization, partly from bioPharma headwinds. The bear case also assumes the BioPharma DDM segment stays near 5% of total revenue from 2026 to 2033, limiting peak revenue to $441M and leaving adjusted gross margins flat at about 70% without meaningful expansion. With the company still not profitable, facing intense competition, cybersecurity and IP risks, and potential dilution from continued equity financing, its path to durable earnings remains uncertain.

SOPH has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

SOPH Analyst Forecast & Price Prediction

Get the latest SOPH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SOPH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 3 analysts, SOPH has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


SOPH Analyst Forecast & Price Prediction

Get the latest SOPH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SOPH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SOPH stock data and trends